Standards of excellence. Models of advocacy. An unparalleled ability to succeed. These are characteristics of the vaccine industry’s top achievers. Last night at the 9th Vaccine Industry Excellence (ViE) Awards, winners were recognized for their outstanding contributions to the vaccine industry over the past 12-months. EpiVax’s own Annie De Groot took home Biotech CEO of the Year, and she is in good company – Sanofi ...

https://www.aaps.org/nationalbiotech/

We’re off to Stockholm for BIO-Europe Spring (BES2016), which will take place 4–6 April in Stockholm, Sweden. We will be joining international leaders from biotech, pharma and finance to identify and enter new strategic relationships. Sign up to meet us now through the partnering system or via email

Lucky us! the 13th International Bio Asia Conference is scheduled for March 15-16, 2016 at the Grand Hyatt, Tokyo in Roppongi. It might be a bit early for cherry blossoms, but hope springs eternal! We will be arriving a bit early and staying a bit late. Please let us know if you would like us to meet with you ...

As a Valentine’s day gift to women at risk of Zika everywhere, we’re providing access to our initial analysis of Zika and our opinion on Zika vaccine design.  If you just want access to the slides, here they are: https://bit.ly/Zika_Slides_EpiVax_2016 What’s the key point of this post? We think that it’s won’t be so easy to make an effective Zika vaccine. Rushing ...

The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...

The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...

(This post has been corrected, thanks Sebastian!) I love “Google Alerts”. They let me know when someone has just published an article citing one of our articles, and link me to new, exciting work that has just been made available on the web. Last week, my google alert linked me to a new paper by Sebastian Spindeldreher’s ...

Our latest mini-publication on ‘vaccines on demand’ can be found here: IQT Quarterly Winter 2016 – EpiVax

Sancha Salgueiro! Congratulations to Sancha and the team at ExpreS2ion Biotechnologies! https://www.linkedin.com/in/sanchasalgueiro

Graduate student Lu He, working with EpiVax CEO De Groot and collaborator Chris Bailey Kellog, recently reported that bacteria ‘copy and paste’ sequences from the human genome to escape immune response. She calls this escape mechanism “bacterial immune camouflage“. She used the JanusMatrix tool to develop a new measure of immune escape,  the Janus Immunogenicity Score ...

An academic version of this blog post, that explains why epitope redundancy provides resiliency (to bacteria) and weakness (to immune defense) can be found here.  . . . So a guy named Elledge has discovered a way to test your blood for the viruses that you’ve been exposed to. Sounds as if it will soon be available ...

An academic version of this blog post, that explains why epitope redundancy provides resiliency (to bacteria) and weakness (to immune defense) can be found here.  . . . So a guy named Elledge has discovered a way to test your blood for the viruses that you’ve been exposed to. Sounds as if it will soon be available ...

PROVIDENCE, R.I., Jan. 11, 2016 /PRNewswire/ — EpiVax, Inc. (EpiVax) today announced the company’s participation in a new venture, Aceno Biotherapeutics, a BioSuperior company. Co-founder Anne S. De Groot MD will be presenting the vision for the new venture in San Francisco at the Hilton Union Square in San Francisco, at 4 PM (Davidson). Aceno ...

A short time ago, we received an email that contained an individual patient’s cancer genome. The patient had appealed to his doctor to make a personalized cancer vaccine, and his doctor emailed us, to ask if we could help out. Our answer? Yes we can! A bigger question might be – how will the patient get permission to ...